search
Back to results

Evaluation of Reactive Focal Mass Drug Administration (rfMDA) +/- Reactive Focal Vector Control (RAVC) in Namibia

Primary Purpose

Malaria

Status
Completed
Phase
Phase 3
Locations
Namibia
Study Type
Interventional
Intervention
RACD
RAVC
rfMDA
Sponsored by
University of California, San Francisco
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Malaria

Eligibility Criteria

6 Months - undefined (Child, Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Index Case Investigation Inclusion Criteria:

    • Malaria infection (either locally transmitted or imported) detected at a health facility via passive surveillance, and
    • Resides in a study Enumeration Area (EA), and
    • Provides informed consent
  2. RACD Intervention Inclusion Criteria:

    • Provides informed consent, and
    • Index case resides in study EA, and
    • All non-index cases that reside or spent at least one night in the Target Area in the past 4 weeks, and
    • Residents of the six houses closest to the index case, and
    • If 25 people are not enrolled in the study at the first six houses, plus the index case household, after the second visit then additional houses can be approached on the third visit.
  3. rfMDA Intervention Inclusion Criteria:

    • Provides informed consent, and
    • Index case resides in study EA, and
    • All non-index cases that reside or spent at least one night in the Target Area in the past 4 weeks, and
    • Residents of the six houses closest to the index case, and
    • If 25 people are not enrolled in the study at the first six houses, plus the index case household, after the second visit then additional houses can be approached on the third visit.
  4. Artemether/Lumefantrine (A-L) (combination medication) Inclusion Criteria:

    • Consent to take A-L medication
    • Does not meet A-L Exclusion Criteria under item #4 below
  5. Pill count Inclusion Criteria:

    • Provides consent, and
    • People who receive any number of RACD or rfMDA drug dose(s)
  6. Reactive Vector Control Inclusion Criteria:

    • Informed consent provided by head of household or person in otherwise in charge of household, and
    • Index case resides in study EA, and
    • Index household and 6 non-index households closest to index household
  7. Endline Survey, Individual, Inclusion Criteria:

    • Provides informed consent, and
    • Resides or spent at least 1 night in the EA in the preceding 4 weeks
  8. Acceptability Assessment: Individual Interviews with study participants, Inclusion Criteria:

    • Provides informed consent, and
    • Resident of index household or of neighbouring households
  9. Acceptability Assessment: Individual Interviews with key stakeholders, Inclusion Criteria:

    • In leadership position within Zambezi region, and
    • Provides informed consent
  10. Acceptability Assessment: Individual Interview with refusers, Inclusion Criteria:

    • Refused to participate in rfMDA, RACD, and/or RAVC, and
    • Provides informed consent to take part in the anonymous survey
  11. Acceptability Assessment: Focus group discussions with study participants, Inclusion Criteria:

    • Provides informed consent, and
    • Was eligible to be enrolled in the study in participant's Target Area, and
    • Either took part in RACD or rfMDA intervention (+/- RAVC), OR refused these interventions

Exclusion Criteria:

  1. Index Case Investigation Exclusion Criteria:

    • Malaria infection identified through active case detection
    • Refusal to participate
  2. RACD Intervention Exclusion Criteria:

    • Index case does not reside in study EA, or
    • Refusal to participate in RACD, or
    • Household received the intervention in the previous 5 weeks, or
    • Household > 500 m from the index case, or
    • Severe or complicated malaria as assessed by study nurse (this will lead to referral for further evaluation at health facility but not enrolment in study)
  3. rfMDA Intervention Exclusion Criteria:

    • Index case does not reside in study EA, or
    • Refusal to participate in rfMDA, or
    • Household received the intervention in the previous 5 weeks, or
    • Household > 500 m from the index case, or
    • Severe or complicated malaria as assessed by study nurse (this will lead to referral for further evaluation at health facility but not enrolment in study)
  4. Artemether/Lumefantrine (combination medication) Exclusion Criteria:

    • Pregnancy in first trimester, or
    • Previous regular menstruation, with no menstruation for most recent 4 weeks, or
    • Weight < 5 kg*, or
    • Severe malaria, or
    • Known allergy to A-L, or
    • Refusal of the offered A-L

      • Note regarding A-L weight exclusion: Because of the pre-set required field at the top of the Eligibility section of this Application, the investigators have indicated a 6 month minimum age limit, primarily to note to the reader that there will be a lower age limit to infants enrolled. Yet during the actual conduct of this trial the investigators will utilize 5 kg weight as the cutoff, rather than using age. A lower weight cutoff of 5 kg is in accordance with A-L's manufacturer (Novartis)'s guidance on supporting pediatric data.
  5. Pill count Exclusion Criteria:

    • Refusal to participate in pill count, or
    • Individuals who did not receive any drug doses through RACD or rfMDA
  6. Reactive Vector Control Exclusion Criteria:

    • Refusal by head of household to participate in RAVC, or
    • Already received RAVC during current transmission season, or
    • Household is > 500 m from index case household (note: refusal to participate in RACD or rfMDA is not an exclusion criterion for RAVC)
  7. Endline Survey, Individual, Exclusion Criteria:

    • Refusal to participate in Endline Survey (note: lack of participation in rfMDA or RACD is not an exclusion criterion)

  8. Acceptability Assessment: Individual Interviews with study participants, Exclusion Criteria:

    • Refusal to participate in Acceptability Assessment, or
    • Speaks language not understood or able to be translated, or
    • Key stakeholder [see below]
    • Age < 15 years
  9. Acceptability Assessment: Individual Interviews with key stakeholders, Exclusion Criteria:

    • Refusal to participate in Acceptability Assessment, or
    • Speaks language not understood or able to be translated, or
    • Not in leadership position
  10. Acceptability Assessment: Individual Interview with refusers, Exclusion Criteria:

    • Refusal to participate in Acceptability Assessment, or
    • Speaks language not understood or able to be translated, or
    • Age < 15 years
  11. Acceptability Assessment: Focus group discussions with study participants, Exclusion Criteria:

    • Refusal to participate in Acceptability Assessment, or
    • Speaks language not understood or able to be translated, or
    • Key stakeholder or in another leadership position, or
    • Age < 15 years

Sites / Locations

  • University of Namibia Multidisciplinary Research Centre

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

RACD without RAVC

RACD+RAVC

rfMDA without RAVC

rfMDA+RAVC

Arm Description

In this arm, subjects will receive RACD without the addition of RAVC.

In this arm, subjects will receive both: (i) reactive case detection (RACD) and (ii) additional reactive vector control (RAVC)

In this arm, subjects will receive reactive focal mass drug administration (rfMDA) without the addition of RAVC.

In this arm, subjects will receive both: (i) reactive focal mass drug administration (rfMDA) and (ii) RAVC.

Outcomes

Primary Outcome Measures

Incidence
Incidence of confirmed, passively identified malaria cases

Secondary Outcome Measures

All-age infection prevalence
The investigators will determine all-age infection prevalence using loop-mediated isothermal amplification (LAMP) during the cross-sectional household survey. This survey will be administered to a sample of residents of all intervention Enumeration Areas in the Study Area at study conclusion.
All-age seroprevalence
The investigators will determine all-age seroprevalence using ELISA during the cross-sectional household survey. This survey will be administered to a sample of residents of all intervention EAs in the Study Area at study conclusion.
Feasibility of attaining coverage
The investigators will compare coverage of each intervention package and determine the feasibility of reaching 80% coverage for each intervention package. For RACD intervention, this equates to the proportion of the population living in the Target Area that receives a finger prick to test for malaria. For TPE intervention, coverage equates to the proportion that receive an initial dose of antimalarial drug (intention to treat analysis). For RAVC intervention, coverage is defined as the proportion of houses in the Target Area that receive reactive Indoor Residual Spraying (IRS).
Safety: Serious adverse events (SAEs)
The investigators will compare the count of serious adverse events (SAEs) relative to the total number of participants receiving an Intervention, across interventions.
Acceptability
Using focus group discussions (FGDs), the investigators will ask two questions: "Was this intervention acceptable to [participant]?" and "Would [participant] participate in this intervention again if given the opportunity?". The investigators will compare the % of "yes" responses to each of these questions, in the TPE versus the RACD arms.
Refusal rates
Refusal rates for each intervention
Cost of intervention
The investigators will collect detailed expenditure data on costs of delivery of the TPE and RACD interventions. Calculations will include costs for all consumables, as well as staff time, which will be prospectively collected every 10th TPE or RACD event. The investigators will compare TPE versus RACD in terms of cost per intervention event as well as cost per population intervened upon.
Medication adherence
The investigators will measure medication adherence in both TPE and RACD by scheduled pill counts in a random subset of subjects receiving each of those interventions.

Full Information

First Posted
September 18, 2015
Last Updated
July 15, 2020
Sponsor
University of California, San Francisco
Collaborators
University of Texas, London School of Hygiene and Tropical Medicine, University of Southampton, The Novartis Foundation, Clinton Health Access Initiative, Nigeria
search

1. Study Identification

Unique Protocol Identification Number
NCT02610400
Brief Title
Evaluation of Reactive Focal Mass Drug Administration (rfMDA) +/- Reactive Focal Vector Control (RAVC) in Namibia
Official Title
Targeted Parasite Elimination in the Human and Mosquito to Reduce Malaria Transmission: A Cluster Randomised Controlled Factorial Design Trial of Reactive Focal Drug Administration (rfMDA) Versus Reactive Case Detection (RACD), With and Without Reactive Vector Control (RAVC), From the Low Endemic Setting of Namibia
Study Type
Interventional

2. Study Status

Record Verification Date
July 2020
Overall Recruitment Status
Completed
Study Start Date
February 2016 (undefined)
Primary Completion Date
December 2017 (Actual)
Study Completion Date
December 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University of California, San Francisco
Collaborators
University of Texas, London School of Hygiene and Tropical Medicine, University of Southampton, The Novartis Foundation, Clinton Health Access Initiative, Nigeria

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a cluster randomised controlled trial with factorial study design comparing the impact of reactive community-based malaria interventions: 1) presumptive treatment (or rfMDA, reactive focal mass drug administration) versus reactive case detection (RACD), and 2) reactive IRS (indoor residual spraying) versus control on the incidence of malaria in Namibia.
Detailed Description
In recent years, many countries, including Namibia, have experienced reductions in malaria transmission in association with the scale-up of effective interventions and are now moving towards malaria elimination. In malaria control, the goal is to reduce the clinical burden of malaria. In malaria elimination, the aim is to interrupt transmission, and it becomes necessary to address not only symptomatic malaria, but also asymptomatic infections that contribute to transmission. Since malaria transmission is highly geographically heterogeneous, elimination activities should target hot spots, or areas where the risk of future infection is highest. Hence, in the transition from control to elimination, enhanced surveillance and response is necessary to target hot spots with interventions to interrupt transmission. Reactive case detection (RACD), active surveillance in communities around passively detected cases, is a recommended elimination strategy to identify secondary cases and hot spots. However, RACD can be labour-, time-, and cost- intensive, and misses people who are absent during screening or refuse to have their blood drawn. Furthermore, both microscopy and rapid diagnostic tests (RDTs) utilized in RACD have shortcomings, for instance, the suboptimal sensitivity of RDTs for low parasite density and non-falciparum infections. Polymerase chain reaction (PCR) offers markedly improved sensitivity over RDTs but requires hours of processing time, sophisticated technical skills, and expensive equipment. Given these limitations, presumptive treatment may be a more feasible and effective strategy to reduce and interrupt transmission. Reactive focal mass drug administration (rfMDA), a form of presumptive treatment, has been used successfully in China to overcome some of the weaknesses of RACD. rfMDA targets remaining reservoirs of infection in low endemic settings by treating everyone at high risk (subjects residing around an index case), rather than rely on RDT results, which have been shown to miss infections. In a low transmission setting such as Namibia, only a small proportion of the populations is at high risk of infection, therefore, only a small number of people need to be targeted (perhaps 20-50 people). Additional indoor residual spraying (IRS) targeted to homes in high risk locations can also be implemented. rfMDA is a promising strategy, but evidence does not yet exist to prove its efficacy in Africa. Questions remain about where to target rfMDA, what drugs to use, and whether drugs should be used alone or in combination with additional vector control. For rfMDA to be most successful, it is necessary to kill parasites in the human as well as the vector population of the target area. However, one challenge of pre-transmission season IRS is that it is difficult to predict where future infections will occur. A reactive approach, in conjunction with the pre-transmission approach, will ensure coverage of effective vector control in the highest risk areas. Further, if there is unknown resistance to the insecticide used during pre-transmission season, the subsequent reactive use of a different, and presumably effective insecticide, will provide better protection. In this study the investigators will utilise a cluster randomized controlled study design to evaluate rfMDA in response to a passively identified index case and compare it to RACD. The investigators will study each intervention (rfMDA, RACD) both with and without additional focal insecticide spraying. 56 enumeration areas (EAs) within catchment areas of 11 study health facilities will be randomized to one of four intervention arms: RACD only RACD with RAVC rfMDA only rfMDA with RAVC A rapid reporting surveillance system will capture confirmed, passively identified cases at all study health facilities, and those cases will trigger an intervention by the study team if located in one of the study EAs.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malaria

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Factorial Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
9845 (Actual)

8. Arms, Groups, and Interventions

Arm Title
RACD without RAVC
Arm Type
Experimental
Arm Description
In this arm, subjects will receive RACD without the addition of RAVC.
Arm Title
RACD+RAVC
Arm Type
Experimental
Arm Description
In this arm, subjects will receive both: (i) reactive case detection (RACD) and (ii) additional reactive vector control (RAVC)
Arm Title
rfMDA without RAVC
Arm Type
Experimental
Arm Description
In this arm, subjects will receive reactive focal mass drug administration (rfMDA) without the addition of RAVC.
Arm Title
rfMDA+RAVC
Arm Type
Experimental
Arm Description
In this arm, subjects will receive both: (i) reactive focal mass drug administration (rfMDA) and (ii) RAVC.
Intervention Type
Combination Product
Intervention Name(s)
RACD
Other Intervention Name(s)
Reactive Case Detection
Intervention Description
Active malaria surveillance using rapid diagnostic test in households around passively-detected index case. RDT-positive subjects are treated per national policy, under which combination medication artemether-lumefantrine is first-line, using dosing (mg artemether / mg lumefantrine): (i) 5-14kg patient: 20/120mg twice (8 hr apart) on day 1, 20/120mg twice (12 hr apart) on each of days 2 and 3 then stop (ii) 15-24kg patient: 40/240mg twice (8 hrs apart) on day 1, 40/240mg twice (12 hrs apart) on each of days 2 and 3 then stop (iii) 25-34kg patient: 60/360mg twice (8 hrs apart) on day 1, 60/360mg twice (12 hrs apart) on each of days 2 and 3 then stop (iv) > 34kg patient: 80/480mg twice (8 hrs apart) on day 1, 80/480mg twice (12 hrs apart) on each of days 2 and 3, then stop
Intervention Type
Combination Product
Intervention Name(s)
RAVC
Other Intervention Name(s)
Reactive Vector Control
Intervention Description
Focal, targeted indoor spraying with long-lasting insecticide pirimiphos-methyl or Actellic 300 CS, a World Health Organization (WHO)-approved organophosphate. Safety measures: (i) seeking advance permission to spray; (ii) temporarily removing items (utensils, water, food, pets) from the building during spray; (iii) covering all unremovable items; (iv) asking inhabitants to temporarily relocate outdoors during spray; (v) advising children remain outdoors until floors washed; and (vi) avoiding of spraying of any rooms that contain inhabitants, animals, or incorrectly removed/covered items. Actellic will be applied according to National Vector-borne Disease Control Program (NVDCP) indoor residual spraying (IRS) guidelines, using a Hudson X-pert sprayer (Hudson Manufacturing Co., Chicago, USA) at 40 mL/m-sq.
Intervention Type
Combination Product
Intervention Name(s)
rfMDA
Other Intervention Name(s)
Reactive focal mass drug administration
Intervention Description
Presumptive treatment, using the medication A-L, of the inhabitants of households surrounding a passively-detected index case, without incorporating a diagnostic test step. The investigators will administer A-L with dosing as follows (mg artemether / mg lumefantrine): (i) 5-14kg patient: 20/120mg twice (8 hours apart) on day 1, 20/120mg twice (12 hours apart) on each of days 2 and 3, then stop (ii) 15-24kg patient: 40/240mg twice (8 hours apart) on day 1, 40/240mg twice (12 hours apart) on each of days 2 and 3, then stop (iii) 25-34kg patient: 60/360mg twice (8 hours apart) on day 1, 60/360mg twice (12 hours apart) on each of days 2 and 3, then stop (iv) > 34kg patient: 80/480mg twice (8 hours apart) on day 1, 80/480mg twice (12 hours apart) on each of days 2 and 3, then stop
Primary Outcome Measure Information:
Title
Incidence
Description
Incidence of confirmed, passively identified malaria cases
Time Frame
Up to 12 months
Secondary Outcome Measure Information:
Title
All-age infection prevalence
Description
The investigators will determine all-age infection prevalence using loop-mediated isothermal amplification (LAMP) during the cross-sectional household survey. This survey will be administered to a sample of residents of all intervention Enumeration Areas in the Study Area at study conclusion.
Time Frame
Up to 12 months
Title
All-age seroprevalence
Description
The investigators will determine all-age seroprevalence using ELISA during the cross-sectional household survey. This survey will be administered to a sample of residents of all intervention EAs in the Study Area at study conclusion.
Time Frame
Up to 12 months
Title
Feasibility of attaining coverage
Description
The investigators will compare coverage of each intervention package and determine the feasibility of reaching 80% coverage for each intervention package. For RACD intervention, this equates to the proportion of the population living in the Target Area that receives a finger prick to test for malaria. For TPE intervention, coverage equates to the proportion that receive an initial dose of antimalarial drug (intention to treat analysis). For RAVC intervention, coverage is defined as the proportion of houses in the Target Area that receive reactive Indoor Residual Spraying (IRS).
Time Frame
Up to 12 months
Title
Safety: Serious adverse events (SAEs)
Description
The investigators will compare the count of serious adverse events (SAEs) relative to the total number of participants receiving an Intervention, across interventions.
Time Frame
Up to 12 months
Title
Acceptability
Description
Using focus group discussions (FGDs), the investigators will ask two questions: "Was this intervention acceptable to [participant]?" and "Would [participant] participate in this intervention again if given the opportunity?". The investigators will compare the % of "yes" responses to each of these questions, in the TPE versus the RACD arms.
Time Frame
Up to 12 months
Title
Refusal rates
Description
Refusal rates for each intervention
Time Frame
Up to 12 months
Title
Cost of intervention
Description
The investigators will collect detailed expenditure data on costs of delivery of the TPE and RACD interventions. Calculations will include costs for all consumables, as well as staff time, which will be prospectively collected every 10th TPE or RACD event. The investigators will compare TPE versus RACD in terms of cost per intervention event as well as cost per population intervened upon.
Time Frame
Up to 12 months
Title
Medication adherence
Description
The investigators will measure medication adherence in both TPE and RACD by scheduled pill counts in a random subset of subjects receiving each of those interventions.
Time Frame
Up to 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
6 Months
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Index Case Investigation Inclusion Criteria: Malaria infection (either locally transmitted or imported) detected at a health facility via passive surveillance, and Resides in a study Enumeration Area (EA), and Provides informed consent RACD Intervention Inclusion Criteria: Provides informed consent, and Index case resides in study EA, and All non-index cases that reside or spent at least one night in the Target Area in the past 4 weeks, and Residents of the six houses closest to the index case, and If 25 people are not enrolled in the study at the first six houses, plus the index case household, after the second visit then additional houses can be approached on the third visit. rfMDA Intervention Inclusion Criteria: Provides informed consent, and Index case resides in study EA, and All non-index cases that reside or spent at least one night in the Target Area in the past 4 weeks, and Residents of the six houses closest to the index case, and If 25 people are not enrolled in the study at the first six houses, plus the index case household, after the second visit then additional houses can be approached on the third visit. Artemether/Lumefantrine (A-L) (combination medication) Inclusion Criteria: Consent to take A-L medication Does not meet A-L Exclusion Criteria under item #4 below Pill count Inclusion Criteria: Provides consent, and People who receive any number of RACD or rfMDA drug dose(s) Reactive Vector Control Inclusion Criteria: Informed consent provided by head of household or person in otherwise in charge of household, and Index case resides in study EA, and Index household and 6 non-index households closest to index household Endline Survey, Individual, Inclusion Criteria: Provides informed consent, and Resides or spent at least 1 night in the EA in the preceding 4 weeks Acceptability Assessment: Individual Interviews with study participants, Inclusion Criteria: Provides informed consent, and Resident of index household or of neighbouring households Acceptability Assessment: Individual Interviews with key stakeholders, Inclusion Criteria: In leadership position within Zambezi region, and Provides informed consent Acceptability Assessment: Individual Interview with refusers, Inclusion Criteria: Refused to participate in rfMDA, RACD, and/or RAVC, and Provides informed consent to take part in the anonymous survey Acceptability Assessment: Focus group discussions with study participants, Inclusion Criteria: Provides informed consent, and Was eligible to be enrolled in the study in participant's Target Area, and Either took part in RACD or rfMDA intervention (+/- RAVC), OR refused these interventions Exclusion Criteria: Index Case Investigation Exclusion Criteria: Malaria infection identified through active case detection Refusal to participate RACD Intervention Exclusion Criteria: Index case does not reside in study EA, or Refusal to participate in RACD, or Household received the intervention in the previous 5 weeks, or Household > 500 m from the index case, or Severe or complicated malaria as assessed by study nurse (this will lead to referral for further evaluation at health facility but not enrolment in study) rfMDA Intervention Exclusion Criteria: Index case does not reside in study EA, or Refusal to participate in rfMDA, or Household received the intervention in the previous 5 weeks, or Household > 500 m from the index case, or Severe or complicated malaria as assessed by study nurse (this will lead to referral for further evaluation at health facility but not enrolment in study) Artemether/Lumefantrine (combination medication) Exclusion Criteria: Pregnancy in first trimester, or Previous regular menstruation, with no menstruation for most recent 4 weeks, or Weight < 5 kg*, or Severe malaria, or Known allergy to A-L, or Refusal of the offered A-L Note regarding A-L weight exclusion: Because of the pre-set required field at the top of the Eligibility section of this Application, the investigators have indicated a 6 month minimum age limit, primarily to note to the reader that there will be a lower age limit to infants enrolled. Yet during the actual conduct of this trial the investigators will utilize 5 kg weight as the cutoff, rather than using age. A lower weight cutoff of 5 kg is in accordance with A-L's manufacturer (Novartis)'s guidance on supporting pediatric data. Pill count Exclusion Criteria: Refusal to participate in pill count, or Individuals who did not receive any drug doses through RACD or rfMDA Reactive Vector Control Exclusion Criteria: Refusal by head of household to participate in RAVC, or Already received RAVC during current transmission season, or Household is > 500 m from index case household (note: refusal to participate in RACD or rfMDA is not an exclusion criterion for RAVC) Endline Survey, Individual, Exclusion Criteria: • Refusal to participate in Endline Survey (note: lack of participation in rfMDA or RACD is not an exclusion criterion) Acceptability Assessment: Individual Interviews with study participants, Exclusion Criteria: Refusal to participate in Acceptability Assessment, or Speaks language not understood or able to be translated, or Key stakeholder [see below] Age < 15 years Acceptability Assessment: Individual Interviews with key stakeholders, Exclusion Criteria: Refusal to participate in Acceptability Assessment, or Speaks language not understood or able to be translated, or Not in leadership position Acceptability Assessment: Individual Interview with refusers, Exclusion Criteria: Refusal to participate in Acceptability Assessment, or Speaks language not understood or able to be translated, or Age < 15 years Acceptability Assessment: Focus group discussions with study participants, Exclusion Criteria: Refusal to participate in Acceptability Assessment, or Speaks language not understood or able to be translated, or Key stakeholder or in another leadership position, or Age < 15 years
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Michelle Hsiang, MD
Organizational Affiliation
University of California, San Francisco
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Namibia Multidisciplinary Research Centre
City
Windhoek
Country
Namibia

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
22303287
Citation
Bousema T, Griffin JT, Sauerwein RW, Smith DL, Churcher TS, Takken W, Ghani A, Drakeley C, Gosling R. Hitting hotspots: spatial targeting of malaria for control and elimination. PLoS Med. 2012 Jan;9(1):e1001165. doi: 10.1371/journal.pmed.1001165. Epub 2012 Jan 31.
Results Reference
background
PubMed Identifier
21035841
Citation
Moonen B, Cohen JM, Snow RW, Slutsker L, Drakeley C, Smith DL, Abeyasinghe RR, Rodriguez MH, Maharaj R, Tanner M, Targett G. Operational strategies to achieve and maintain malaria elimination. Lancet. 2010 Nov 6;376(9752):1592-603. doi: 10.1016/S0140-6736(10)61269-X. Epub 2010 Oct 28.
Results Reference
background
PubMed Identifier
11196487
Citation
Carter R, Mendis KN, Roberts D. Spatial targeting of interventions against malaria. Bull World Health Organ. 2000;78(12):1401-11. Epub 2003 Nov 17.
Results Reference
background
PubMed Identifier
22238621
Citation
Hsiang MS, Hwang J, Kunene S, Drakeley C, Kandula D, Novotny J, Parizo J, Jensen T, Tong M, Kemere J, Dlamini S, Moonen B, Angov E, Dutta S, Ockenhouse C, Dorsey G, Greenhouse B. Surveillance for malaria elimination in Swaziland: a national cross-sectional study using pooled PCR and serology. PLoS One. 2012;7(1):e29550. doi: 10.1371/journal.pone.0029550. Epub 2012 Jan 6.
Results Reference
background
PubMed Identifier
23700437
Citation
Sturrock HJ, Novotny JM, Kunene S, Dlamini S, Zulu Z, Cohen JM, Hsiang MS, Greenhouse B, Gosling RD. Reactive case detection for malaria elimination: real-life experience from an ongoing program in Swaziland. PLoS One. 2013 May 20;8(5):e63830. doi: 10.1371/journal.pone.0063830. Print 2013.
Results Reference
background
PubMed Identifier
24175930
Citation
Hsiang MS, Hwang J, Tao AR, Liu Y, Bennett A, Shanks GD, Cao J, Kachur SP, Feachem RG, Gosling RD, Gao Q. Mass drug administration for the control and elimination of Plasmodium vivax malaria: an ecological study from Jiangsu province, China. Malar J. 2013 Nov 1;12:383. doi: 10.1186/1475-2875-12-383.
Results Reference
background
PubMed Identifier
24476070
Citation
Oxborough RM, Kitau J, Jones R, Feston E, Matowo J, Mosha FW, Rowland MW. Long-lasting control of Anopheles arabiensis by a single spray application of micro-encapsulated pirimiphos-methyl (Actellic(R) 300 CS). Malar J. 2014 Jan 29;13:37. doi: 10.1186/1475-2875-13-37.
Results Reference
background
PubMed Identifier
15696210
Citation
White NJ. Intermittent presumptive treatment for malaria. PLoS Med. 2005 Jan;2(1):e3. doi: 10.1371/journal.pmed.0020003.
Results Reference
background
PubMed Identifier
19948038
Citation
Katrak S, Gasasira A, Arinaitwe E, Kakuru A, Wanzira H, Bigira V, Sandison TG, Homsy J, Tappero JW, Kamya MR, Dorsey G. Safety and tolerability of artemether-lumefantrine versus dihydroartemisinin-piperaquine for malaria in young HIV-infected and uninfected children. Malar J. 2009 Nov 30;8:272. doi: 10.1186/1475-2875-8-272.
Results Reference
background
PubMed Identifier
24386988
Citation
Banek K, Lalani M, Staedke SG, Chandramohan D. Adherence to artemisinin-based combination therapy for the treatment of malaria: a systematic review of the evidence. Malar J. 2014 Jan 6;13:7. doi: 10.1186/1475-2875-13-7.
Results Reference
background
PubMed Identifier
35738650
Citation
Ntuku H, Smith-Gueye C, Scott V, Njau J, Whittemore B, Zelman B, Tambo M, Prach LM, Wu L, Schrubbe L, Kang Dufour MS, Mwilima A, Uusiku P, Sturrock H, Bennett A, Smith J, Kleinschmidt I, Mumbengegwi D, Gosling R, Hsiang M. Cost and cost effectiveness of reactive case detection (RACD), reactive focal mass drug administration (rfMDA) and reactive focal vector control (RAVC) to reduce malaria in the low endemic setting of Namibia: an analysis alongside a 2x2 factorial design cluster randomised controlled trial. BMJ Open. 2022 Jun 23;12(6):e049050. doi: 10.1136/bmjopen-2021-049050.
Results Reference
derived
PubMed Identifier
32334702
Citation
Hsiang MS, Ntuku H, Roberts KW, Dufour MK, Whittemore B, Tambo M, McCreesh P, Medzihradsky OF, Prach LM, Siloka G, Siame N, Gueye CS, Schrubbe L, Wu L, Scott V, Tessema S, Greenhouse B, Erlank E, Koekemoer LL, Sturrock HJW, Mwilima A, Katokele S, Uusiku P, Bennett A, Smith JL, Kleinschmidt I, Mumbengegwi D, Gosling R. Effectiveness of reactive focal mass drug administration and reactive focal vector control to reduce malaria transmission in the low malaria-endemic setting of Namibia: a cluster-randomised controlled, open-label, two-by-two factorial design trial. Lancet. 2020 Apr 25;395(10233):1361-1373. doi: 10.1016/S0140-6736(20)30470-0.
Results Reference
derived
PubMed Identifier
29374672
Citation
Medzihradsky OF, Kleinschmidt I, Mumbengegwi D, Roberts KW, McCreesh P, Dufour MK, Uusiku P, Katokele S, Bennett A, Smith J, Sturrock H, Prach LM, Ntuku H, Tambo M, Didier B, Greenhouse B, Gani Z, Aerts A, Gosling R, Hsiang MS. Study protocol for a cluster randomised controlled factorial design trial to assess the effectiveness and feasibility of reactive focal mass drug administration and vector control to reduce malaria transmission in the low endemic setting of Namibia. BMJ Open. 2018 Jan 27;8(1):e019294. doi: 10.1136/bmjopen-2017-019294.
Results Reference
derived
Links:
URL
https://globalhealthsciences.ucsf.edu/sites/globalhealthsciences.ucsf.edu/files/pub/mei-pb-review-of-mda-and-primaquine.pdf
Description
Global Health Group Review of Mass Drug Administration and Primaquine Use

Learn more about this trial

Evaluation of Reactive Focal Mass Drug Administration (rfMDA) +/- Reactive Focal Vector Control (RAVC) in Namibia

We'll reach out to this number within 24 hrs